China Resources Pharmaceutical Group Ltd. logo

China Resources Pharmaceutical Group Ltd.

3320.HK

HKSEHealthcareMedical - Pharmaceuticals

Latest quote

HK$4.705

−HK$0.105 · -2.18%

Aug 24, 3:59 PM HKT

3320.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
HK
CEO
Xiaosong Bai
Listed since
Oct 28, 2016
Employees
85,600

Market position

Volume
11.05M
1.06× average
Average volume
10.41M
Average daily volume
Market cap
29.56B HKD
Beta
-0.39
Market reference 1

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.1349

2025 complete year+12.4% since 2021

2026 partial: HK$0.139

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 17, 2026

HK$0.139

Irregular

Record Jun 18, 2026 · Payment Aug 3, 2026

Dividend

Ex-dividend Sep 11, 2025

HK$0.0789

Semi-Annual

Record Sep 12, 2025 · Payment Oct 31, 2025

Dividend

Ex-dividend May 28, 2025

HK$0.056

Semi-Annual

Record May 29, 2025 · Payment Jul 14, 2025

Dividend

Ex-dividend Sep 10, 2024

HK$0.0908

Semi-Annual

Record Sep 11, 2024 · Payment Oct 30, 2024

Dividend

Ex-dividend Jun 4, 2024

HK$0.1697

Semi-Annual

Record Jun 5, 2024 · Payment Jul 19, 2024

Dividend

Ex-dividend Jun 5, 2023

HK$0.16

Annual

Record Jun 6, 2023 · Payment Jul 21, 2023

3320.HK peers

Continue in GoAI

Research 3320.HK

research.disclaimer